Total Payments
$311,616
2024 Payments
$38,336
Companies
21
Transactions
340
Medicare Patients
843
Medicare Billing
$111,639
Payment Breakdown by Category
Consulting$208,906 (67.0%)
Other$69,648 (22.4%)
Research$18,035 (5.8%)
Travel$7,592 (2.4%)
Food & Beverage$7,435 (2.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $208,906 | 83 | 67.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $42,693 | 25 | 13.7% |
| Honoraria | $26,955 | 3 | 8.7% |
| Unspecified | $18,035 | 22 | 5.8% |
| Travel and Lodging | $7,592 | 31 | 2.4% |
| Food and Beverage | $7,435 | 176 | 2.4% |
Payments by Type
General
$293,581
318 transactions
Research
$18,035
22 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $124,626 | 67 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $69,257 | 68 | $0 (2024) |
| Janssen Biotech, Inc. | $46,392 | 83 | $0 (2024) |
| ABBVIE INC. | $24,099 | 59 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $12,125 | 6 | $0 (2022) |
| Eli Lilly and Company | $7,191 | 6 | $0 (2024) |
| Janssen Global Services, LLC | $7,094 | 7 | $0 (2018) |
| UCB, Inc. | $5,940 | 1 | $0 (2021) |
| Celgene Corporation | $3,563 | 25 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $2,788 | 5 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $38,336 | 39 | Janssen Biotech, Inc. ($15,398) |
| 2023 | $24,257 | 34 | Janssen Biotech, Inc. ($7,586) |
| 2022 | $30,470 | 57 | PFIZER INC. ($17,787) |
| 2021 | $59,479 | 59 | PFIZER INC. ($28,926) |
| 2020 | $37,295 | 21 | PFIZER INC. ($26,715) |
| 2019 | $62,440 | 66 | PFIZER INC. ($32,170) |
| 2018 | $37,840 | 30 | Takeda Pharmaceuticals U.S.A., Inc. ($19,396) |
| 2017 | $21,500 | 34 | Takeda Pharmaceuticals U.S.A., Inc. ($14,725) |
All Payment Transactions
340 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/21/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Consulting Fee | Cash or cash equivalent | $2,125.00 | General |
| Category: Immunology | ||||||
| 12/18/2024 | ABBVIE INC. | RINVOQ (Biological) | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/18/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $22.21 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/09/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $143.04 | General |
| Category: Immunology | ||||||
| 12/07/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $38.42 | General |
| Category: Immunology | ||||||
| 12/04/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Immunology | ||||||
| 11/11/2024 | AIMMUNE THERAPEUTICS, INC. | VOWST (Biological) | Food and Beverage | In-kind items and services | $25.64 | General |
| Category: GI | ||||||
| 11/07/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $4.58 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/06/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $16.19 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 10/27/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $25.19 | General |
| Category: IMMUNOLOGY | ||||||
| 10/22/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Consulting Fee | Cash or cash equivalent | $2,711.25 | General |
| Category: INTERNAL MEDICINE | ||||||
| 10/22/2024 | Biocon Biologics Inc | Yesintek (Biological) | Consulting Fee | Cash or cash equivalent | $2,593.35 | General |
| Category: Rheumatology | ||||||
| 08/07/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $22.26 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 07/10/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $22.71 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 06/12/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $33.62 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 05/15/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $21.88 | General |
| Category: Neuroscience | ||||||
| 04/25/2024 | Eli Lilly and Company | OMVOH (Drug) | Consulting Fee | Cash or cash equivalent | $3,600.00 | General |
| Category: Immunology | ||||||
| 04/25/2024 | Eli Lilly and Company | OMVOH (Drug) | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| Category: Immunology | ||||||
| 04/18/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $202.32 | General |
| 04/18/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $201.41 | General |
| 04/18/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $198.10 | General |
| 04/18/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $189.35 | General |
| 03/19/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Travel and Lodging | Cash or cash equivalent | $361.50 | General |
| Category: Immunology | ||||||
| 03/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $29.17 | General |
| Category: Neuroscience | ||||||
| 03/05/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Consulting Fee | Cash or cash equivalent | $11,050.00 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TOFACITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $15,380 | 14 |
| TOFACITINIB IBD CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $2,180 | 2 |
| M16-009 | AbbVie, Inc. | $475.39 | 6 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 193 | 270 | $376,343 | $23,827 |
| 2022 | 6 | 212 | 289 | $463,662 | $27,385 |
| 2021 | 5 | 196 | 281 | $473,634 | $28,721 |
| 2020 | 8 | 242 | 367 | $412,155 | $31,705 |
Total Patients
843
Total Services
1,207
Medicare Billing
$111,639
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 113 | 188 | $103,400 | $14,625 | 14.1% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Office | 2023 | 48 | 48 | $223,200 | $7,047 | 3.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 21 | 23 | $8,625 | $1,384 | 16.0% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Office | 2023 | 11 | 11 | $41,118 | $770.77 | 1.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 107 | 183 | $100,650 | $13,972 | 13.9% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Office | 2022 | 46 | 46 | $213,900 | $6,057 | 2.8% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Office | 2022 | 15 | 15 | $77,640 | $3,487 | 4.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 11 | 11 | $11,715 | $1,886 | 16.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 19 | 20 | $7,425 | $1,002 | 13.5% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Office | 2022 | 14 | 14 | $52,332 | $981.77 | 1.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 106 | 188 | $103,400 | $15,750 | 15.2% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Office | 2021 | 45 | 48 | $212,995 | $6,279 | 2.9% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Office | 2021 | 15 | 15 | $75,378 | $3,486 | 4.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 11 | 11 | $11,715 | $1,750 | 14.9% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Office | 2021 | 19 | 19 | $70,146 | $1,456 | 2.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 97 | 204 | $112,200 | $16,177 | 14.4% |
| 45380 | Biopsy of large bowel using an endoscope | Office | 2020 | 41 | 42 | $162,330 | $5,814 | 3.6% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope | Office | 2020 | 13 | 13 | $52,585 | $3,210 | 6.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 18 | 33 | $12,045 | $2,179 | 18.1% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 11 | 11 | $11,715 | $1,893 | 16.2% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Office | 2020 | 15 | 15 | $49,500 | $1,076 | 2.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 11 | 11 | $6,050 | $813.12 | 13.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 14 | 14 | $5,250 | $471.82 | 9.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2020 | 22 | 24 | $480.00 | $71.40 | 14.9% |
About Dr. David Hudesman, M.D
Dr. David Hudesman, M.D is a Gastroenterology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/22/2008. The National Provider Identifier (NPI) number assigned to this provider is 1538326970.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Hudesman, M.D has received a total of $311,616 in payments from pharmaceutical and medical device companies, with $38,336 received in 2024. These payments were reported across 340 transactions from 21 companies. The most common payment nature is "Consulting Fee" ($208,906).
As a Medicare-enrolled provider, Hudesman has provided services to 843 Medicare beneficiaries, totaling 1,207 services with total Medicare billing of $111,639. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location New York, NY
- Active Since 05/22/2008
- Last Updated 04/12/2021
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1538326970
Products in Payments
- XELJANZ (Drug) $80,870
- Entyvio (Biological) $54,877
- STELARA (Biological) $38,403
- TREMFYA (Drug) $17,869
- ENTYVIO (Biological) $12,715
- VELSIPITY (Drug) $9,525
- SKYRIZI (Biological) $8,152
- ZEPOSIA (Drug) $7,588
- Humira (Biological) $6,983
- OMVOH (Drug) $6,400
- RINVOQ (Biological) $3,327
- Yesintek (Biological) $2,593
- HUMIRA (Biological) $2,361
- APRISO (Drug) $2,000
- CYLTEZO (Drug) $1,965
- UCERIS (Drug) $650.00
- IDACIO (Biological) $610.00
- Hera W10 (Device) $50.00
- Beacon (Device) $47.11
- RENFLEXIS (Drug) $29.06
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in New York
Arthur Kornbluth, Md, MD
Gastroenterology — Payments: $2.4M
Gastroenterology $2.4M
Dr. David Carr-Locke, Md Frcp Facg Masge, MD FRCP FACG MASGE
Gastroenterology — Payments: $2.3M
Gastroenterology $2.3M
Jean-Frederic Colombel, M.d, M.D
Gastroenterology — Payments: $1.1M
Gastroenterology $1.1M
Dr. Bruce Sands, Md, MD
Gastroenterology — Payments: $1.0M
Gastroenterology $1.0M
Ellen Scherl, Md, MD
Gastroenterology — Payments: $880,329
Gastroenterology $880,329
Sonal Kumar, Md, MD
Gastroenterology — Payments: $769,554
Gastroenterology $769,554